Cambridge Healthtech Institute's Twelfth Annual Biomarkers & Diagnostics World Congress 2016 is dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline. The meeting brings together a unique and international mix of large and medium pharmaceutical, biotech and diagnostics companies, leading universities and clinical research institutions, government and national labs, CROs, emerging companies and tool providers—making the Congress a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies. The World Congress will continue offering comprehensive coverage of biomarkers, including translational biomarkers in drug discovery, patient selection biomarkers, strategies to co-develop drugs with companion diagnostics, cell-free DNA and RNA, as well as coverage of big data for personalized medicine. New additions this year will include a track on Biomarkers for Cancer Immunotherapy, as well as two pre-conference symposia, covering biomarker assay development and exosomes.
